Physician profile
Hector Puig-Ramirez
NPI 1467414276
$7,606.55
in general payments reported to CMS, 2019-2025
17 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,512 · 2020: $356 · 2021: $619 · 2022: $978 · 2023: $917 · 2024: $789 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,729.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,887.73 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,436.57 | 2019-2023 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $253.51 | 2023-2025 | Winrevair, Capvaxive, Vaxneuvance |
| Genzyme Corporation | $229.61 | 2021-2025 | |
| United Therapeutics Corporation | $228.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $188.42 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.62 | 2019-2022 | |
| Mylan Specialty L.P. | $125.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $123.90 | 2022 | |
| Genentech USA, INC. | $71.80 | 2019 | |
| Amgen INC. | $63.67 | 2024-2025 | Tezspire |
| Gilead Sciences, INC. | $39.68 | 2023 | |
| Jazz Pharmaceuticals INC. | $32.53 | 2024 | |
| Grifols USA, LLC | $22.81 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.40 | 2025 | General - Angioplasty |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.54 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Puig-Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.